Our team

An experienced team of biopharmaceutical leaders

We have assembled a strong scientific, medchem, management, and commercial team based in Finland and the US. Our scientific team has published seminal papers on the structural, functional, and biological mechanisms of PP2A inactivation in human cancer.

Management
Mikko Mannerkoski

Mikko Mannerkoski

Chief Executive Officer

Goutham Narla, M.D., Ph.D.

Goutham Narla, M.D., Ph.D.

Chief Scientific Officer

George Trainor, Ph.D.

George Trainor, Ph.D.

Head of Chemistry

Pekka Kallio, Ph.D.

Pekka Kallio, Ph.D.

Head of Operations

Derek Taylor, Ph.D.

Derek Taylor, Ph.D.

Head of Structural Biology

Erkki Tenhunen

Erkki Tenhunen

Head of Business Development

Jukka Hiltunen, Ph.D.

Jukka Hiltunen, Ph.D.

Head of IP

Investors
Beat Steffen, M.D.

Beat Steffen, M.D.

Chairperson

Jeroen Bakker, Ph.D.

Jeroen Bakker, Ph.D.

Board Member

Raj Parekh, Ph.D.

Raj Parekh, Ph.D.

Board Member

Scientific Advisory Board
William C. Hahn, M.D., Ph.D.

William C. Hahn, M.D., Ph.D.

Chairperson of the Advisory Board

David L. Brautigan, Ph.D.

David L. Brautigan, Ph.D.

Scientific Adviser

Arul M. Chinnaiyan, M.D., Ph.D.

Arul M. Chinnaiyan, M.D., Ph.D.

Scientific Adviser

Donald P. McDonnell, Ph.D.

Donald P. McDonnell, Ph.D.

Scientific Adviser

Rosalie C. Sears, Ph.D.

Rosalie C. Sears, Ph.D.

Scientific Adviser

Advisers
Sinikka Demaré, CFA

Sinikka Demaré, CFA

Strategic Adviser